Joaquim Bellmunt
MD, PhD
Director, Bladder Cancer Center
👥Biography 个人简介
Joaquim Bellmunt led the pivotal KEYNOTE-045 trial that established pembrolizumab as the first immunotherapy to demonstrate overall survival benefit in platinum-refractory urothelial carcinoma, leading to FDA approval. His research has long focused on prognostic factors and novel systemic therapies for advanced bladder cancer. He contributed to development of the Bellmunt risk score for metastatic urothelial cancer that continues to be used in clinical practice. He is co-director of the Bladder Cancer Center at Beth Israel Deaconess Medical Center.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Joaquim Bellmunt 的研究动态
Follow Joaquim Bellmunt's research updates
留下邮箱，当我们发布与 Joaquim Bellmunt（Beth Israel Deaconess Medical Center, Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment